ID   RB6I2_HUMAN             Reviewed;        1116 AA.
AC   Q8IUD2; A2RU77; A7E295; D3DUP7; D3DUP8; Q6NVK2; Q8IUD3; Q8IUD4; Q8IUD5;
AC   Q8NAS1; Q9NXN5; Q9UIK7; Q9UPS1;
DT   31-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   18-JUN-2025, entry version 208.
DE   RecName: Full=ELKS/Rab6-interacting/CAST family member 1;
DE            Short=ERC-1;
DE   AltName: Full=Rab6-interacting protein 2;
GN   Name=ERC1; Synonyms=ELKS, KIAA1081, RAB6IP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND CHROMOSOMAL TRANSLOCATION WITH
RP   RET.
RX   PubMed=10337992;
RX   DOI=10.1002/(sici)1098-2264(199906)25:2<97::aid-gcc4>3.0.co;2-l;
RA   Nakata T., Kitamura Y., Shimizu K., Tanaka S., Fujimori M., Yokoyama S.,
RA   Ito K., Emi M.;
RT   "Fusion of a novel gene, ELKS, to RET due to translocation
RT   t(10;12)(q11;p13) in a papillary thyroid carcinoma.";
RL   Genes Chromosomes Cancer 25:97-103(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 5), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=12203787; DOI=10.1002/gcc.10095;
RA   Nakata T., Yokota T., Emi M., Minami S.;
RT   "Differential expression of multiple isoforms of the ELKS mRNAs involved in
RT   a papillary thyroid carcinoma.";
RL   Genes Chromosomes Cancer 35:30-37(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 1-652 (ISOFORM 3).
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1061 (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10470851; DOI=10.1093/dnares/6.3.197;
RA   Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N., Tanaka A.,
RA   Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIV. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:197-205(1999).
RN   [6]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [7]
RP   PROTEIN SEQUENCE OF 254-269, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 733-1116 (ISOFORM 2), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 828-1116 (ISOFORMS 1/3).
RC   TISSUE=Colon;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH CHUK; IKBKB; IKBKG AND NFKBIA.
RX   PubMed=15218148; DOI=10.1126/science.1098387;
RA   Ducut Sigala J.L., Bottero V., Young D.B., Shevchenko A., Mercurio F.,
RA   Verma I.M.;
RT   "Activation of transcription factor NF-kappaB requires ELKS, an IkappaB
RT   kinase regulatory subunit.";
RL   Science 304:1963-1967(2004).
RN   [10]
RP   INTERACTION WITH PPFIA1.
RX   PubMed=12923177; DOI=10.1074/jbc.m307561200;
RA   Ko J., Na M., Kim S., Lee J.R., Kim E.;
RT   "Interaction of the ERC family of RIM-binding proteins with the liprin-
RT   alpha family of multidomain proteins.";
RL   J. Biol. Chem. 278:42377-42385(2003).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17; SER-21 AND THR-1046, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-75, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-94, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17 AND SER-21, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   SUBUNIT, AND INTERACTION WITH KANK1.
RX   PubMed=24120883; DOI=10.1016/j.devcel.2013.09.010;
RA   van der Vaart B., van Riel W.E., Doodhi H., Kevenaar J.T., Katrukha E.A.,
RA   Gumy L., Bouchet B.P., Grigoriev I., Spangler S.A., Yu K.L., Wulf P.S.,
RA   Wu J., Lansbergen G., van Battum E.Y., Pasterkamp R.J., Mimori-Kiyosue Y.,
RA   Demmers J., Olieric N., Maly I.V., Hoogenraad C.C., Akhmanova A.;
RT   "CFEOM1-associated kinesin KIF21A is a cortical microtubule growth
RT   inhibitor.";
RL   Dev. Cell 27:145-160(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37 AND THR-38, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   SUBUNIT.
RX   PubMed=27410476; DOI=10.7554/elife.18124;
RA   Bouchet B.P., Gough R.E., Ammon Y.C., van de Willige D., Post H.,
RA   Jacquemet G., Altelaar A.M., Heck A.J., Goult B.T., Akhmanova A.;
RT   "Talin-KANK1 interaction controls the recruitment of cortical microtubule
RT   stabilizing complexes to focal adhesions.";
RL   Elife 5:0-0(2016).
RN   [20]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH SDCCAG8.
RX   PubMed=27224062; DOI=10.1371/journal.pone.0156081;
RA   Airik R., Schueler M., Airik M., Cho J., Ulanowicz K.A., Porath J.D.,
RA   Hurd T.W., Bekker-Jensen S., Schroeder J.M., Andersen J.S., Hildebrandt F.;
RT   "SDCCAG8 interacts with RAB effector proteins RABEP2 and ERC1 and is
RT   required for Hedgehog Signaling.";
RL   PLoS ONE 11:E0156081-E0156081(2016).
CC   -!- FUNCTION: Regulatory subunit of the IKK complex. Probably recruits
CC       IkappaBalpha/NFKBIA to the complex. May be involved in the organization
CC       of the cytomatrix at the nerve terminals active zone (CAZ) which
CC       regulates neurotransmitter release. May be involved in vesicle
CC       trafficking at the CAZ. May be involved in Rab-6 regulated endosomes to
CC       Golgi transport. {ECO:0000269|PubMed:15218148}.
CC   -!- SUBUNIT: Part of a complex with CHUK, IKBKB and IKBKG. Interacts with
CC       CHUK, IKBKB and IKBKG. The interaction with IKBKG is independent of
CC       CHUK and IKBKB. Interacts with NFKBIA. Isoform 4 interacts with PPFIA1,
CC       and through its C-terminus with the PDZ domains of RIMS1 and RIMS2.
CC       Interacts with ERC2/CAST1. Interacts with the GTB-bound forms of RAB6A
CC       isoform 1 and isoform 2 and with RAB6B. The interaction was strongest
CC       with RAB6B, followed by RAB6A isoform 2 and weakest with RAB6A isoform
CC       1 (By similarity). Interacts with SDCCAG8. Part of a cortical
CC       microtubule stabilization complex (CMSC) composed of KANK1, PPFIA1,
CC       PPFIBP1, ERC1/ELKS, PHLDB2/LL5beta, CLASPs, KIF21A and possibly
CC       additional interactors; within CMSCs KANK1 and PHLDB2/LL5beta appear to
CC       be the core components for targeting of microtubule-binding proteins
CC       KIF21A and CLASPs, whereas PPFIA1, PPFIBP1 and ERC1/ELKS serve as
CC       scaffolds for protein clustering. {ECO:0000250,
CC       ECO:0000269|PubMed:24120883, ECO:0000269|PubMed:27224062,
CC       ECO:0000269|PubMed:27410476}.
CC   -!- INTERACTION:
CC       Q8IUD2-2; Q8R0S4: Cacnb4; Xeno; NbExp=2; IntAct=EBI-6920871, EBI-3647752;
CC       Q8IUD2-3; PRO_0000037573 [P27958]; Xeno; NbExp=8; IntAct=EBI-9352449, EBI-3649474;
CC       Q8IUD2-4; PRO_0000037573 [P27958]; Xeno; NbExp=3; IntAct=EBI-9352501, EBI-3649474;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome {ECO:0000269|PubMed:27224062}. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q811U3}. Membrane {ECO:0000250}; Peripheral
CC       membrane protein {ECO:0000250}. Golgi apparatus membrane {ECO:0000250};
CC       Peripheral membrane protein {ECO:0000250}. Presynaptic cell membrane
CC       {ECO:0000250|UniProtKB:Q811U3}. Cell projection, podosome
CC       {ECO:0000250|UniProtKB:Q99MI1}. Note=Recruited on Golgi membranes by
CC       RAB6A in a GTP-dependent manner (By similarity). Localized to the
CC       cortex of myotube podosomes (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q99MI1}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=ELKS epsilon;
CC         IsoId=Q8IUD2-1; Sequence=Displayed;
CC       Name=2; Synonyms=ELKS beta;
CC         IsoId=Q8IUD2-2; Sequence=VSP_011451, VSP_011452, VSP_011454,
CC                                  VSP_011455;
CC       Name=3; Synonyms=ELKS delta;
CC         IsoId=Q8IUD2-3; Sequence=VSP_011451;
CC       Name=4; Synonyms=ELKS alpha;
CC         IsoId=Q8IUD2-4; Sequence=VSP_011451, VSP_011452, VSP_011453,
CC                                  VSP_011454, VSP_011455;
CC       Name=5; Synonyms=ELKS gamma;
CC         IsoId=Q8IUD2-5; Sequence=VSP_011450, VSP_011452, VSP_011454,
CC                                  VSP_011455;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Isoform 2 and isoform 4 are
CC       abundantly expressed in brain. Isoform 1 and isoform 3 are
CC       predominantly expressed in testis and thyroid, and isoform 1
CC       predominates in other tissues tested. {ECO:0000269|PubMed:12203787}.
CC   -!- DISEASE: Note=A chromosomal aberration involving ERC1/RAB6IP2 is found
CC       in papillary thyroid carcinomas (PTCs). Translocation t(10;12)(q11;p13)
CC       involving RET. In vitro, isoform 1, isoform 3 and isoform 5
CC       participating in a ERC1-RET fusion protein activate tyrosine-protein
CC       kinase activity. {ECO:0000269|PubMed:10337992}.
CC   -!- MISCELLANEOUS: [Isoform 2]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH68006.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=BAA83033.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA90975.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/503/ELKS";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB015617; BAA88763.1; -; mRNA.
DR   EMBL; AB053469; BAC54108.1; -; mRNA.
DR   EMBL; AB053468; BAC54107.1; -; mRNA.
DR   EMBL; AB053470; BAC54109.1; -; mRNA.
DR   EMBL; AB053471; BAC54110.1; -; mRNA.
DR   EMBL; CH471116; EAW88932.1; -; Genomic_DNA.
DR   EMBL; CH471116; EAW88934.1; -; Genomic_DNA.
DR   EMBL; CH471116; EAW88936.1; -; Genomic_DNA.
DR   EMBL; CH471116; EAW88938.1; -; Genomic_DNA.
DR   EMBL; BC068006; AAH68006.1; ALT_SEQ; mRNA.
DR   EMBL; BC132782; AAI32783.1; -; mRNA.
DR   EMBL; BC132784; AAI32785.1; -; mRNA.
DR   EMBL; BC150248; AAI50249.1; -; mRNA.
DR   EMBL; AB029004; BAA83033.2; ALT_INIT; mRNA.
DR   EMBL; AK000148; BAA90975.1; ALT_INIT; mRNA.
DR   EMBL; AK092201; BAC03827.1; -; mRNA.
DR   CCDS; CCDS53732.1; -. [Q8IUD2-3]
DR   CCDS; CCDS8508.1; -. [Q8IUD2-1]
DR   RefSeq; NP_829883.1; NM_178039.4. [Q8IUD2-3]
DR   RefSeq; NP_829884.1; NM_178040.4. [Q8IUD2-1]
DR   RefSeq; XP_011519243.1; XM_011520941.2.
DR   RefSeq; XP_016874553.1; XM_017019064.2. [Q8IUD2-1]
DR   RefSeq; XP_016874556.1; XM_017019067.2. [Q8IUD2-3]
DR   RefSeq; XP_047284521.1; XM_047428565.1. [Q8IUD2-1]
DR   RefSeq; XP_047284522.1; XM_047428566.1. [Q8IUD2-1]
DR   RefSeq; XP_047284523.1; XM_047428567.1. [Q8IUD2-1]
DR   RefSeq; XP_047284530.1; XM_047428574.1. [Q8IUD2-3]
DR   RefSeq; XP_047284531.1; XM_047428575.1. [Q8IUD2-3]
DR   RefSeq; XP_047284532.1; XM_047428576.1. [Q8IUD2-3]
DR   RefSeq; XP_054227483.1; XM_054371508.1. [Q8IUD2-1]
DR   RefSeq; XP_054227484.1; XM_054371509.1. [Q8IUD2-1]
DR   RefSeq; XP_054227485.1; XM_054371510.1. [Q8IUD2-1]
DR   RefSeq; XP_054227493.1; XM_054371518.1. [Q8IUD2-3]
DR   RefSeq; XP_054227494.1; XM_054371519.1. [Q8IUD2-3]
DR   RefSeq; XP_054227495.1; XM_054371520.1. [Q8IUD2-3]
DR   RefSeq; XP_054227507.1; XM_054371532.1. [Q8IUD2-2]
DR   RefSeq; XP_054227510.1; XM_054371535.1. [Q8IUD2-4]
DR   AlphaFoldDB; Q8IUD2; -.
DR   SMR; Q8IUD2; -.
DR   BioGRID; 116714; 199.
DR   CORUM; Q8IUD2; -.
DR   FunCoup; Q8IUD2; 1427.
DR   IntAct; Q8IUD2; 102.
DR   MINT; Q8IUD2; -.
DR   STRING; 9606.ENSP00000354158; -.
DR   GlyGen; Q8IUD2; 8 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (7 sites).
DR   iPTMnet; Q8IUD2; -.
DR   MetOSite; Q8IUD2; -.
DR   PhosphoSitePlus; Q8IUD2; -.
DR   BioMuta; ERC1; -.
DR   DMDM; 51827892; -.
DR   jPOST; Q8IUD2; -.
DR   MassIVE; Q8IUD2; -.
DR   PaxDb; 9606-ENSP00000468263; -.
DR   PeptideAtlas; Q8IUD2; -.
DR   ProteomicsDB; 70547; -. [Q8IUD2-1]
DR   ProteomicsDB; 70548; -. [Q8IUD2-2]
DR   ProteomicsDB; 70549; -. [Q8IUD2-3]
DR   ProteomicsDB; 70550; -. [Q8IUD2-4]
DR   ProteomicsDB; 70551; -. [Q8IUD2-5]
DR   Pumba; Q8IUD2; -.
DR   Antibodypedia; 10295; 174 antibodies from 32 providers.
DR   DNASU; 23085; -.
DR   Ensembl; ENST00000347735.10; ENSP00000340054.6; ENSG00000082805.21. [Q8IUD2-4]
DR   Ensembl; ENST00000360905.9; ENSP00000354158.3; ENSG00000082805.21. [Q8IUD2-1]
DR   Ensembl; ENST00000397203.7; ENSP00000380386.4; ENSG00000082805.21. [Q8IUD2-1]
DR   Ensembl; ENST00000440394.7; ENSP00000410064.2; ENSG00000082805.21. [Q8IUD2-2]
DR   Ensembl; ENST00000543086.7; ENSP00000438546.1; ENSG00000082805.21. [Q8IUD2-3]
DR   Ensembl; ENST00000545948.5; ENSP00000442976.1; ENSG00000082805.21. [Q8IUD2-5]
DR   Ensembl; ENST00000589028.6; ENSP00000468263.1; ENSG00000082805.21. [Q8IUD2-1]
DR   GeneID; 23085; -.
DR   KEGG; hsa:23085; -.
DR   MANE-Select; ENST00000360905.9; ENSP00000354158.3; NM_178040.4; NP_829884.1.
DR   UCSC; uc001qjb.3; human. [Q8IUD2-1]
DR   AGR; HGNC:17072; -.
DR   CTD; 23085; -.
DR   DisGeNET; 23085; -.
DR   GeneCards; ERC1; -.
DR   HGNC; HGNC:17072; ERC1.
DR   HPA; ENSG00000082805; Low tissue specificity.
DR   MalaCards; ERC1; -.
DR   MIM; 607127; gene.
DR   OpenTargets; ENSG00000082805; -.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   Orphanet; 280325; Distal deletion 12p syndrome.
DR   VEuPathDB; HostDB:ENSG00000082805; -.
DR   eggNOG; KOG4809; Eukaryota.
DR   GeneTree; ENSGT00650000093320; -.
DR   HOGENOM; CLU_009304_0_0_1; -.
DR   InParanoid; Q8IUD2; -.
DR   OrthoDB; 2019763at2759; -.
DR   PAN-GO; Q8IUD2; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; Q8IUD2; -.
DR   PathwayCommons; Q8IUD2; -.
DR   SignaLink; Q8IUD2; -.
DR   SIGNOR; Q8IUD2; -.
DR   BioGRID-ORCS; 23085; 9 hits in 1159 CRISPR screens.
DR   CD-CODE; F345034F; Signaling cluster.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; ERC1; human.
DR   GeneWiki; ERC1; -.
DR   GenomeRNAi; 23085; -.
DR   Pharos; Q8IUD2; Tbio.
DR   PRO; PR:Q8IUD2; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q8IUD2; protein.
DR   Bgee; ENSG00000082805; Expressed in sural nerve and 198 other cell types or tissues.
DR   ExpressionAtlas; Q8IUD2; baseline and differential.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0008385; C:IkappaB kinase complex; IDA:UniProtKB.
DR   GO; GO:0002102; C:podosome; ISS:UniProtKB.
DR   GO; GO:0098831; C:presynaptic active zone cytoplasmic component; IBA:GO_Central.
DR   GO; GO:0042734; C:presynaptic membrane; TAS:UniProtKB.
DR   GO; GO:0045202; C:synapse; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0030165; F:PDZ domain binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0031267; F:small GTPase binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0098882; F:structural constituent of presynaptic active zone; IBA:GO_Central.
DR   GO; GO:0007252; P:I-kappaB phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048790; P:maintenance of presynaptic active zone structure; IBA:GO_Central.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0042147; P:retrograde transport, endosome to Golgi; ISS:ParkinsonsUK-UCL.
DR   FunFam; 1.20.5.2440:FF:000005; ELKS/Rab6-interacting/CAST family member 1 isoform X1; 1.
DR   Gene3D; 1.10.287.1490; -; 1.
DR   Gene3D; 1.20.5.2440; -; 1.
DR   Gene3D; 1.20.5.340; -; 1.
DR   InterPro; IPR019323; ELKS/CAST.
DR   InterPro; IPR037245; FIP-RBD_C_sf.
DR   InterPro; IPR019018; Rab-bd_FIP-RBD.
DR   PANTHER; PTHR18861; ELKS/RAB6-INTERACTING/CAST PROTEIN; 1.
DR   PANTHER; PTHR18861:SF1; ELKS_RAB6-INTERACTING_CAST FAMILY MEMBER 1; 1.
DR   Pfam; PF10174; Cast; 3.
DR   Pfam; PF09457; RBD-FIP; 1.
DR   SUPFAM; SSF144270; Eferin C-derminal domain-like; 1.
DR   SUPFAM; SSF90257; Myosin rod fragments; 1.
DR   SUPFAM; SSF57997; Tropomyosin; 1.
DR   PROSITE; PS51511; FIP_RBD; 1.
DR   neXtProt; NX_Q8IUD2; -.
DR   PharmGKB; PA134970875; -.
DR   TreeFam; TF324969; -.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Cell junction; Cell membrane;
KW   Cell projection; Chromosomal rearrangement; Coiled coil; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Golgi apparatus; Membrane;
KW   Phosphoprotein; Protein transport; Proteomics identification;
KW   Reference proteome; Synapse; Transport.
FT   CHAIN           1..1116
FT                   /note="ELKS/Rab6-interacting/CAST family member 1"
FT                   /id="PRO_0000097176"
FT   DOMAIN          1046..1108
FT                   /note="FIP-RBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00844"
FT   REGION          1..54
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          590..609
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          814..836
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          144..988
FT                   /evidence="ECO:0000255"
FT   COILED          1060..1100
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        13..28
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        40..51
FT                   /note="Gly residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        590..602
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            719..720
FT                   /note="Breakpoint for translocation to form ERC1-RET
FT                   oncogene"
FT   MOD_RES         10
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99MI1"
FT   MOD_RES         17
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         21
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         37
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         38
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         55
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q99MI1"
FT   MOD_RES         75
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         94
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         1005
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q811U3"
FT   MOD_RES         1046
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   VAR_SEQ         224..523
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:12203787"
FT                   /id="VSP_011450"
FT   VAR_SEQ         440..467
FT                   /note="Missing (in isoform 2, isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10337992,
FT                   ECO:0000303|PubMed:10470851, ECO:0000303|PubMed:12203787,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_011451"
FT   VAR_SEQ         783
FT                   /note="E -> ESLTS (in isoform 2, isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:10337992,
FT                   ECO:0000303|PubMed:10470851, ECO:0000303|PubMed:12203787,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_011452"
FT   VAR_SEQ         830..873
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10337992"
FT                   /id="VSP_011453"
FT   VAR_SEQ         1009..1016
FT                   /note="IIQPLLEL -> DEEEGIWA (in isoform 2, isoform 4 and
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:10337992,
FT                   ECO:0000303|PubMed:10470851, ECO:0000303|PubMed:12203787,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_011454"
FT   VAR_SEQ         1017..1116
FT                   /note="Missing (in isoform 2, isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:10337992,
FT                   ECO:0000303|PubMed:10470851, ECO:0000303|PubMed:12203787,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_011455"
FT   VARIANT         50
FT                   /note="S -> G (in dbSNP:rs35037408)"
FT                   /id="VAR_051304"
FT   VARIANT         1032
FT                   /note="T -> A (in dbSNP:rs12319376)"
FT                   /id="VAR_051305"
FT   CONFLICT        828
FT                   /note="L -> G (in Ref. 8; BAA90975)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        892
FT                   /note="K -> R (in Ref. 8; BAC03827)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        910
FT                   /note="T -> I (in Ref. 8; BAC03827)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1021
FT                   /note="S -> G (in Ref. 8; BAA90975)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1116 AA;  128086 MW;  CCB70380AA7C6E69 CRC64;
     MYGSARSVGK VEPSSQSPGR SPRLPRSPRL GHRRTNSTGG SSGSSVGGGS GKTLSMENIQ
     SLNAAYATSG PMYLSDHENV GSETPKSTMT LGRSGGRLPY GVRMTAMGSS PNIASSGVAS
     DTIAFGEHHL PPVSMASTVP HSLRQARDNT IMDLQTQLKE VLRENDLLRK DVEVKESKLS
     SSMNSIKTFW SPELKKERAL RKDEASKITI WKEQYRVVQE ENQHMQMTIQ ALQDELRIQR
     DLNQLFQQDS SSRTGEPCVA ELTEENFQRL HAEHERQAKE LFLLRKTLEE MELRIETQKQ
     TLNARDESIK KLLEMLQSKG LSAKATEEDH ERTRRLAEAE MHVHHLESLL EQKEKENSML
     REEMHRRFEN APDSAKTKAL QTVIEMKDSK ISSMERGLRD LEEEIQMLKS NGALSTEERE
     EEMKQMEVYR SHSKFMKNKV EQLKEELSSK EAQWEELKKK AAGLQAEIGQ VKQELSRKDT
     ELLALQTKLE TLTNQFSDSK QHIEVLKESL TAKEQRAAIL QTEVDALRLR LEEKETMLNK
     KTKQIQDMAE EKGTQAGEIH DLKDMLDVKE RKVNVLQKKI ENLQEQLRDK EKQMSSLKER
     VKSLQADTTN TDTALTTLEE ALAEKERTIE RLKEQRDRDE REKQEEIDNY KKDLKDLKEK
     VSLLQGDLSE KEASLLDLKE HASSLASSGL KKDSRLKTLE IALEQKKEEC LKMESQLKKA
     HEAALEARAS PEMSDRIQHL EREITRYKDE SSKAQAEVDR LLEILKEVEN EKNDKDKKIA
     ELERQVKDQN KKVANLKHKE QVEKKKSAQM LEEARRREDN LNDSSQQLQD SLRKKDDRIE
     ELEEALRESV QITAEREMVL AQEESARTNA EKQVEELLMA MEKVKQELES MKAKLSSTQQ
     SLAEKETHLT NLRAERRKHL EEVLEMKQEA LLAAISEKDA NIALLELSSS KKKTQEEVAA
     LKREKDRLVQ QLKQQTQNRM KLMADNYEDD HFKSSHSNQT NHKPSPDQII QPLLELDQNR
     SKLKLYIGHL TTLCHDRDPL ILRGLTPPAS YNLDDDQAAW ENELQKMTRG QLQDELEKGE
     RDNAELQEFA NAILQQIADH CPDILEQVVN ALEESS
//
